Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Saphnelo (Anifrolumab) is instrumental in addressing autoimmune conditions by targeting and inhibiting the type I interferon receptor. Since this receptor is frequently overactive in autoimmune ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

This disease is primarily treated with off-label drugs or newer meds in the form of GSK's Benlysta and AstraZeneca's Saphnelo. The most common form of the disease is systemic lupus erythematosus ...

So, that's exciting news. The anifrolumab trial is moving along nicely. And so we might know soon, whether or not we might have an anti-interferon agent available for the treatment of lupus nephritis.

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial Trial continues as planned to 52 weeks to further ...

At close: March 26 at 5:29:51 PM GMT+1 Loading Chart for AZN.ST ...